PHARM Stock Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Pharming Group N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.01 |
52 Week High | €1.31 |
52 Week Low | €0.93 |
Beta | 0.74 |
1 Month Change | -3.90% |
3 Month Change | -3.54% |
1 Year Change | -19.67% |
3 Year Change | -8.65% |
5 Year Change | 20.23% |
Change since IPO | -98.93% |
Recent News & Updates
Recent updates
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Feb 20Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price
Oct 29Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly
Jun 03Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)
May 12Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?
Mar 15Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly
Feb 15We Think Pharming Group's (AMS:PHARM) Statutory Profit Might Understate Its Earnings Potential
Jan 28Did You Miss Pharming Group's (AMS:PHARM) Whopping 350% Share Price Gain?
Jan 05Shareholder Returns
PHARM | NL Biotechs | NL Market | |
---|---|---|---|
7D | -2.2% | 4.3% | 2.7% |
1Y | -19.7% | -2.7% | 19.3% |
Return vs Industry: PHARM underperformed the Dutch Biotechs industry which returned -1.1% over the past year.
Return vs Market: PHARM underperformed the Dutch Market which returned 21.7% over the past year.
Price Volatility
PHARM volatility | |
---|---|
PHARM Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.7% |
10% most volatile stocks in NL Market | 8.0% |
10% least volatile stocks in NL Market | 2.3% |
Stable Share Price: PHARM has not had significant price volatility in the past 3 months.
Volatility Over Time: PHARM's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 332 | Simon de Vries | https://www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases.
Pharming Group N.V. Fundamentals Summary
PHARM fundamental statistics | |
---|---|
Market cap | €677.11m |
Earnings (TTM) | -€9.35m |
Revenue (TTM) | €226.60m |
3.0x
P/S Ratio-72.4x
P/E RatioIs PHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHARM income statement (TTM) | |
---|---|
Revenue | US$245.32m |
Cost of Revenue | US$25.21m |
Gross Profit | US$220.10m |
Other Expenses | US$230.22m |
Earnings | -US$10.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 04, 2024
Earnings per share (EPS) | -0.015 |
Gross Margin | 89.72% |
Net Profit Margin | -4.12% |
Debt/Equity Ratio | 63.2% |
How did PHARM perform over the long term?
See historical performance and comparison